Trastuzumab Rechallenge After Lapatinib- and Trastuzumab-Resistant Disease Progression in HER2-Positive Breast Cancer

摘要

Optimal management has yet to be established for lapatinib- and trastuzumab-resistant HER2-advanced disease progression. In this retrospective study we focused on 50 patients re-treated with trastuzumab after trastuzumab-and lapatinib-resistant disease progression. Various chemotherapies in combination with trastuzumab rechallenge had different efficacy regardless of whether previous anti-HER2 therapies had clinical benefits. Trastuzumab rechallenge combined with various chemotherapies is effective against some anti-HER2 therapy-resistant HER2-positive disease.